跳至主要内容
临床试验/IRCT20151227025726N20
IRCT20151227025726N20已完成2 期

Evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Patients between 18 and 65 years old.
  • Laboratory confirmed COVID-19 (Corona Virus Disease-19) with RT-PCR (Real-Time Polymerase Chain Reaction).
  • Severely ill patients.
  • Bilateral pulmonary infiltration.
  • SPO2 (Peripheral Capillary Oxygen Saturation) less than 90% (at rest with nasal cannula 3-4 L/min and FIO2 less than 30-40 L/min).
  • Signed consent form.

排除标准

  • Allergy reaction while injecting IVIG with severe extravasation and anaphylactic shock.
  • Mildly ill patient.
  • Pregnancy or breast feeding.

研究者

相似试验